The honest answer: there is no published evidence that BPC-157 causes cancer. There is also no long-term human data that could prove it does not. The concern people raise is theoretical, and it comes from the very mechanism that makes BPC-157 interesting: new blood-vessel growth. This review lays out where the worry comes from, what the toxicology and tumour-model studies actually reported, and what remains genuinely unknown.
Why people ask this question
Search “BPC-157” and “cancer” shows up within a few suggestions. The reason is a chain of three facts that are each true:
- BPC-157 is studied for promoting angiogenesis, the growth of new blood vessels.
- Research by Hsieh and colleagues (2017) associated that effect with activation and up-regulation of VEGFR2, a key growth-factor receptor.
- Solid tumours need new blood vessels to grow beyond a few millimetres, and VEGF signalling is a classic cancer target.
Put together, the question is fair: could a molecule that encourages vessel growth also help an existing tumour grow? That is a hypothesis, not a finding. Here is how the evidence lines up against it.
Angiogenesis: a double-edged mechanism
Angiogenesis is not inherently good or bad. It is how wounds heal, how muscle adapts to exercise and how the body restores blood flow after injury. It is also how tumours recruit a blood supply. Biology uses the same tools for repair and for disease, which is exactly why context matters.
| Healthy repair | Tumour growth | |
|---|---|---|
| Trigger | Injury, low oxygen in damaged tissue | Signals from cancer cells |
| Duration | Temporary, switches off when healed | Persistent and disorganized |
| Vessel quality | Organized, mature vessels | Leaky, chaotic vessels |
A compound that supports repair-type angiogenesis does not automatically drive tumour-type angiogenesis. But it is also not safe to simply assume it cannot, which is why direct data matters.
What the studies actually report
Toxicology studies
A preclinical safety evaluation published by Xu and colleagues in 2020 (Regulatory Toxicology and Pharmacology) examined BPC-157 in several animal species and reported no significant toxicity across the doses and durations tested. Toxicology studies of this kind look for organ damage and abnormal findings over weeks to months; they are not designed to detect cancer that might take years to develop.
Tumour models
The Zagreb group that produced most BPC-157 research has published work in tumour-bearing animals, examining effects such as tumour-associated cachexia (muscle wasting). Those studies did not report that BPC-157 accelerated tumour growth. They are, however, small, mostly from one research network and not designed as definitive cancer-safety studies.
Human data
There are no large, long-term human trials of BPC-157. Without them, no one can make a confident claim about cancer risk in either direction.
Summary of the evidence: no study has reported that BPC-157 causes or accelerates cancer. Toxicology work in animals reported no significant toxicity. Long-term human safety data does not exist.
What we genuinely do not know
- Long-term exposure. Animal toxicology covers weeks to months; cancer can take years to appear.
- Pre-existing tumours. Whether a pro-angiogenic peptide could affect an undiagnosed tumour has not been directly studied in controlled human research.
- Independent replication. Most BPC-157 work comes from one research group. Independent confirmation, in either direction, is limited.
- Product quality. In the real market, the unknown is often not BPC-157 itself but what is actually in a given vial. An unverified product adds risk that no study can measure. That is why a batch-specific COA matters.
How to put the risk in context
Absence of evidence is not evidence of absence. The scientifically honest position is “no signal so far, insufficient data to rule it out,” and that is the same position that applies to most research peptides. Anyone with a personal or family history of cancer who is reading about these compounds should speak with an oncologist or physician; that conversation is beyond what any website, including this one, can responsibly answer.
The verdict
| Claim | Status |
|---|---|
| “BPC-157 causes cancer” | Not supported by any published study |
| “BPC-157 is proven safe long-term” | Not supported either: no long-term human data |
| “The concern is theoretical, based on angiogenesis” | Accurate |
| “Animal toxicology found no significant toxicity” | Accurate, within the doses and durations tested |
For the full research picture, read our BPC-157 Canada guide and the side-by-side BPC-157 vs TB-500 comparison.
Frequently asked questions
Cliquez sur une question pour afficher la réponse.
Does BPC-157 cause cancer?
No published study has reported that BPC-157 causes or accelerates cancer. The concern is theoretical and stems from its pro-angiogenic activity. Long-term human safety data does not exist.
Why is BPC-157 linked to cancer concerns?
Because it is studied for promoting new blood-vessel growth and VEGFR2 signalling, mechanisms that tumours also use to grow.
Has BPC-157 been tested for toxicity?
Yes. A 2020 preclinical safety evaluation in several animal species reported no significant toxicity across the doses and durations tested.
Is BPC-157 approved in Canada?
No. It is not approved by Health Canada and is sold in Canada as a research chemical for laboratory use only.
Selected references
- Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med. 2017. PubMed
- Xu C, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020. PubMed
- Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. PubMed
- Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 2007;6(4):273–286. PubMed
All TrueLabs products are sold for in vitro and laboratory research use only. They are not intended for human or veterinary use. This article is an evidence summary, not medical advice. If you have concerns about cancer, please talk to a physician.